Our results show that XRCC3 favours the growth of MCF-7 xenografts since the growth rate of tumours was roughly five times higher for XRCC3 over-expressing cells when compared to the control type (i.e. 57% vs. 12% respectively). Here, XRCC3 is linked to neoplasm.